Lv1
10 积分 2024-07-09 加入
Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade
25天前
已完结
Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1+ Non–Small Cell Lung Cancer Patients
2个月前
已完结
Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1+ Non–Small Cell Lung Cancer Patients
3个月前
已完结
Clinical application of circulating tumour DNA in colorectal cancer
4个月前
已完结
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study
6个月前
已完结
Antibody–drug conjugates in gastric cancer: from molecular landscape to clinical strategies
6个月前
已完结
Molecular pathogenesis, targeted therapies, and future perspectives for gastric cancer
6个月前
已完结
PARP抑制剂在mCRPC中疗效和安全性的研究进展
10个月前
已完结
皖公网安备34019202002308
